ClinicalTrials.gg
CompletedNCT03256695Updated Nov 9, 2021Results posted

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Albuterol sulfate (ABS) in Chronic Obstructive Pulmonary Disease, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 40 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, 1 under way, none of them phase 3. Albuterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
2nd of 27
405 · median 33
Started
2017
with 1 other
Phase 3
6 of 27
none open now
Registered
22nd of 27
by date
Lead sponsor
2 of 27
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 3, and was the 22nd registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between as-needed usage of albuterol eMDPI and Clinical Exacerbation-Chronic Obstructive Pulmonary Disease (CE-COPD) in adult participants at least 40 years of age with exacerbation-prone COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has had at least 1 episode of moderate or severe CE- over the past 12 months before screening.
  • The participant must be able to demonstrate appropriate use of albuterol from the ABS eMDPI.
  • The participant is currently using a short-acting beta agonist (SABA) reliever plus at least one of the following: long-acting beta agonist (LABA), an inhaled (ICS)/LABA, a long-acting muscarinic antagonist (LAMA), or a LABA/LAMA.
  • The participant must be willing and able to comply with study requirements as specified in the protocol, including the use of a wearable accelerometer for the subset of participants who consent to use of the device.
  • The participant is willing to discontinue all other rescue or maintenance SABA or antimuscarinic agents and replace them with the study-provided ABS eMDPI for the duration of the trial.
  • Women of (not surgically sterile or greater than or equal to [≥]2 years ) must have exclusively same-sex partners or use a highly effective method of and must agree to continue the use of this method for the duration of the study and for 30 days after discontinuation of the medicinal product (IMP).

    • Additional criteria apply, please contact the investigator for more information.

Exclusion criteria

Exclusion Criteria:

  • The participant has any medical condition (treated or untreated) that, in the opinion of the investigator, would interfere with participation in the study.
  • The participant has any other confounding underlying lung disorder other than .
  • The participant has used an drug within 5 half-lives of it being discontinued or within1 month of Visit 2 (Baseline [Day 1]), whichever is longer.
  • The participant is a pregnant or lactating woman, or plans to become pregnant during the study. Note: Any woman becoming pregnant during the study will be withdrawn from the study.
  • The participant is known to be allergic to albuterol or any of the in the IMP or rescue medication formulation (that is, lactose [milk protein]). Dietary lactose intolerance does not exclude the participant from inclusion in the study or as per the investigator's medical discretion.
  • The participant has a history or presence of "silent" infections, including positive testing for types 1 and 2, , , and tuberculosis.

    • Additional criteria apply, please contact the investigator for more information.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    ABS eMDPI

    Participants will receive 90 micrograms (mcg) of albuterol sulfate (ABS) via eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks. ABS eMDPI is a rescue/reliever agent that includes an eModule on top of the approved PROAIR RESPICLICK® inhaler. Participants will be allowed to continue use of other COPD and non-COPD medications as advised by their physician without changes unless deemed necessary by their physician.

    Drug: Albuterol sulfate (ABS)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD

    CE-COPD was an occurrence of either severe CE-COPD or moderate CE-COPD. Severe CE-COPD was defined as an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with systemic corticosteroids (SCS; at least 10 milligrams \[mg\] prednisone equivalent above baseline) and/or systemic antibiotics and a hospitalization for CE COPD. Moderate CE-COPD was defined as an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline), and/or systemic antibiotics, and an unscheduled encounter (such as a phone call, an office visit, an urgent care visit, or an emergency care visit) for a CE-COPD, but not a hospitalization.

    Time frame: Baseline (Day 1) to Week 12

  2. Total Number of Albuterol Inhalations in the Days Preceding the Symptom Peak of a CE-COPD Event

    Severe CE-COPD: an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline) and/or systemic antibiotics and a hospitalization. Moderate CE-COPD: an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline), and/or systemic antibiotics, and an unscheduled encounter (such as a phone call, office visit, urgent care visit, or emergency care visit), but not a hospitalization. Total number of inhalations taken in 1 day(24-hour period on day prior to date of CE-COPD symptom peak) and at 3,5,7,10,14, and 21 days preceding the date of CE-COPD symptom peak were reported. If a participant experienced multiple CE-COPD events, number of inhalations preceding symptom peak of a subsequent event was counted since end of previous event. Average of inhalations of all events were presented.

    Time frame: Baseline to Week 12

  3. Number of Days Prior to the Symptom Peak of a CE-COPD Event When Albuterol Use Increased

    CE-COPD: occurrence of moderate or severe CE-COPD. Severe CE-COPD: an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline) and/or systemic antibiotics and a hospitalization. Moderate CE-COPD: an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline), and/or systemic antibiotics, and an unscheduled encounter (such as a phone call, an office visit, an urgent care visit, or an emergency care visit), but not a hospitalization. Number of days of increased albuterol use prior to the symptom peak of a CE-COPD was reported for first increase of daily albuterol use; 2 and 4 inhalations in a single day from baseline. increased daily albuterol use was defined as single-day increase of greater than (\>) 20 percent (%) from baseline.

    Time frame: Baseline to Week 12

  4. Number of Albuterol Uses in the 24 Hours Preceding a CE-COPD

    CE-COPD referred to occurrence of moderate or severe CE-COPD. Severe CE-COPD was defined as an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline) and/or systemic antibiotics and a hospitalization for CE COPD. Moderate CE-COPD was defined as an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline), and/or systemic antibiotics, and an unscheduled encounter (such as a phone call, an office visit, an urgent care visit, or an emergency care visit) for a CE-COPD, but not a hospitalization. Number of albuterol inhalations used in the 24 hours preceding a moderate or severe CE-COPD was reported.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by investigator. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

    Time frame: Baseline up to Week 12

07

Results

Posted Aug 6, 2019

Participant flow

Participant flow — Overall Study
MilestoneABS eMDPI
Started405
Used abs emdpi at least once390
Completed366
Not completed39
Withdrew: Adverse event8
Withdrew: Death2
Withdrew: Withdrawal by subject14
Withdrew: Non-compliance with study drug1
Withdrew: Lost to follow-up3
Withdrew: Lack of efficacy3
Withdrew: Protocol violation5
Withdrew: Other than specified3

Outcome measures

PrimaryClinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD

CE-COPD was an occurrence of either severe CE-COPD or moderate CE-COPD. Severe CE-COPD was defined as an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with systemic corticosteroids (SCS; at least 10 milligrams \[mg\] prednisone equivalent above baseline) and/or systemic antibiotics and a hospitalization for CE COPD. Moderate CE-COPD was defined as an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline), and/or systemic antibiotics, and an unscheduled encounter (such as a phone call, an office visit, an urgent care visit, or an emergency care visit) for a CE-COPD, but not a hospitalization.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Number · percentage of participants
Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD
percentage of participantsABS eMDPI
Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD28
PrimaryTotal Number of Albuterol Inhalations in the Days Preceding the Symptom Peak of a CE-COPD Event

Severe CE-COPD: an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline) and/or systemic antibiotics and a hospitalization. Moderate CE-COPD: an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline), and/or systemic antibiotics, and an unscheduled encounter (such as a phone call, office visit, urgent care visit, or emergency care visit), but not a hospitalization. Total number of inhalations taken in 1 day(24-hour period on day prior to date of CE-COPD symptom peak) and at 3,5,7,10,14, and 21 days preceding the date of CE-COPD symptom peak were reported. If a participant experienced multiple CE-COPD events, number of inhalations preceding symptom peak of a subsequent event was counted since end of previous event. Average of inhalations of all events were presented.

Time frame:
Baseline to Week 12
Reported as:
Mean · inhalations
Total Number of Albuterol Inhalations in the Days Preceding the Symptom Peak of a CE-COPD Event
inhalationsABS eMDPI
Day 1 prior to CE-COPD symptom peak3.7 ± 4.36
Day 3 prior to CE-COPD symptom peak3.5 ± 4.61
Day 5 prior to CE-COPD symptom peak4.2 ± 5.35
Day 7 prior to CE-COPD symptom peak3.4 ± 4.45
Day 10 prior to CE-COPD symptom peak3.2 ± 4.41
Day 14 prior to CE-COPD symptom peak3.4 ± 4.42
Day 21 prior to CE-COPD symptom peak3.1 ± 4.54
PrimaryNumber of Days Prior to the Symptom Peak of a CE-COPD Event When Albuterol Use Increased

CE-COPD: occurrence of moderate or severe CE-COPD. Severe CE-COPD: an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline) and/or systemic antibiotics and a hospitalization. Moderate CE-COPD: an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline), and/or systemic antibiotics, and an unscheduled encounter (such as a phone call, an office visit, an urgent care visit, or an emergency care visit), but not a hospitalization. Number of days of increased albuterol use prior to the symptom peak of a CE-COPD was reported for first increase of daily albuterol use; 2 and 4 inhalations in a single day from baseline. increased daily albuterol use was defined as single-day increase of greater than (\>) 20 percent (%) from baseline.

Time frame:
Baseline to Week 12
Reported as:
Mean · days
Number of Days Prior to the Symptom Peak of a CE-COPD Event When Albuterol Use Increased
daysABS eMDPI
Days from albuterol use >20% increase to CE-COPD32.7 ± 19.92
Days from 2 inhalations increase to CE-COPD31.2 ± 21.30
Days from 4 inhalations increase to CE-COPD30.4 ± 21.24
PrimaryNumber of Albuterol Uses in the 24 Hours Preceding a CE-COPD

CE-COPD referred to occurrence of moderate or severe CE-COPD. Severe CE-COPD was defined as an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline) and/or systemic antibiotics and a hospitalization for CE COPD. Moderate CE-COPD was defined as an event that involved worsening respiratory symptoms for at least 2 consecutive days requiring treatment with SCS (at least 10 mg prednisone equivalent above baseline), and/or systemic antibiotics, and an unscheduled encounter (such as a phone call, an office visit, an urgent care visit, or an emergency care visit) for a CE-COPD, but not a hospitalization. Number of albuterol inhalations used in the 24 hours preceding a moderate or severe CE-COPD was reported.

Time frame:
Baseline to Week 12
Reported as:
Mean · inhalations/24 hours
Number of Albuterol Uses in the 24 Hours Preceding a CE-COPD
inhalations/24 hoursABS eMDPI
Number of Albuterol Uses in the 24 Hours Preceding a CE-COPD3.7 ± 4.36
SecondaryNumber of Participants With Adverse Events (AEs)

AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by investigator. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsABS eMDPI
Any AEs190
Severe AEs43
Treatment-related AEs2
Treatment-related severe AE0
Serious AEs44
AEs leading to discontinuation from study8
CE-COPD related AEs118
Device-related AEs0
AEs leading to death2

Adverse events

Collected over AEs were collected from signature of the informed consent form (ICF) to Week 12.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABS eMDPI2/405 (0.5%)44/405 (10.9%)94/405 (23.2%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventABS eMDPI
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders22/405
PneumoniaInfections and infestations5/405
Acute respiratory failureRespiratory, thoracic and mediastinal disorders5/405
Myocardial infarctionCardiac disorders2/405
Chest painGeneral disorders2/405
InfluenzaInfections and infestations2/405
SepsisInfections and infestations2/405
SyncopeNervous system disorders2/405
Acute left ventricular failureCardiac disorders1/405
Acute myocardial infarctionCardiac disorders1/405
Most frequent other events
Most frequent other events
EventABS eMDPI
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders94/405

Baseline characteristics

The intent-to-treat (ITT) analysis set included all enrolled participants regardless of whether a participant took any investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)ABS eMDPI
Mean65.6 ± 8.70
Sex: Female, Male
Sex: Female, Male(Participants)ABS eMDPI
Female220
Male185
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ABS eMDPI
Hispanic or Latino34
Not Hispanic or Latino371
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABS eMDPI
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American38
White365
More than one race0
Unknown or Not Reported0
Number of COPD Exacerbations in the Past 12 Months
Number of COPD Exacerbations in the Past 12 Months(exacerbations)ABS eMDPI
Mean1.5 ± 0.98
08

Study locations

40 sites
  • Teva Investigational Site 14682
    Andalusia, Alabama 36420, United States
  • Teva Investigational Site 14704
    Anniston, Alabama 36207, United States
  • Teva Investigational Site 14712
    Mobile, Alabama 36608, United States
  • Teva Investigational Site 14702
    Peoria, Arizona 85381, United States
  • Teva Investigational Site 14706
    Gold River, California 95670, United States
  • Teva Investigational Site 14720
    Waterbury, Connecticut 06708, United States
  • Teva Investigational Site 14725
    Brandon, Florida 33511, United States
  • Teva Investigational Site 14711
    Daytona Beach, Florida 32117, United States
  • Teva Investigational Site 14699
    DeLand, Florida 32720, United States
  • Teva Investigational Site 14694
    Edgewater, Florida 32132, United States
  • Teva Investigational Site 14701
    Miami, Florida 33126, United States
  • Teva Investigational Site 14689
    Miami, Florida 33135, United States
  • Teva Investigational Site 14678
    Miami, Florida 33155, United States
  • Teva Investigational Site 14688
    Orlando, Florida 32825, United States
  • Teva Investigational Site 14679
    Valparaiso, Indiana 46383, United States
  • Teva Investigational Site 14677
    North Dartmouth, Massachusetts 02747, United States
  • Teva Investigational Site 14705
    Chesterfield, Missouri 63017, United States
  • Teva Investigational Site 14717
    Omaha, Nebraska 68114, United States
  • Teva Investigational Site 14684
    Toms River, New Jersey 08755, United States
  • Teva Investigational Site 14710
    Charlotte, North Carolina 28207, United States
  • Teva Investigational Site 14696
    Gastonia, North Carolina 28054, United States
  • Teva Investigational Site 14722
    Greensboro, North Carolina 27408, United States
  • Teva Investigational Site 14692
    Winston-Salem, North Carolina 27103, United States
  • Teva Investigational Site 14708
    Columbus, Ohio 43215, United States
  • Teva Investigational Site 14703
    Dayton, Ohio 45458, United States
  • Teva Investigational Site 14680
    Grove City, Ohio 43123, United States
  • Teva Investigational Site 14709
    Toledo, Ohio 43617, United States
  • Teva Investigational Site 14724
    Willoughby, Ohio 44094, United States
  • Teva Investigational Site 14683
    Pittsburgh, Pennsylvania 15243, United States
  • Teva Investigational Site 14681
    Charleston, South Carolina 29406, United States
  • Teva Investigational Site 14686
    Easley, South Carolina 29640, United States
  • Teva Investigational Site 14719
    Gaffney, South Carolina 29341, United States
  • Teva Investigational Site 14691
    Greenville, South Carolina 29615, United States
  • Teva Investigational Site 14695
    Mount Pleasant, South Carolina 29464, United States
  • Teva Investigational Site 14715
    Spartanburg, South Carolina 29303, United States
  • Teva Investigational Site 14718
    Spartanburg, South Carolina 29303, United States
  • Teva Investigational Site 14707
    Union, South Carolina 29379, United States
  • Teva Investigational Site 14716
    San Antonio, Texas 78229, United States
  • Teva Investigational Site 14713
    Richmond, Virginia 23225, United States
  • Teva Investigational Site 14687
    Spokane, Washington 99204, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Apr 2018, 6 months.

Results were first posted in Aug 2019, 1 year 3 months after primary completion.

Of 109 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 6 months is below that.

Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Aug 22, 2017
StartActual
Sep 28, 2017
Primary completionActual
Apr 17, 2018
CompletionActual
Apr 17, 2018
Results first posted
Aug 6, 2019
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03256695
Responsible party
Sponsor
First posted
Aug 22, 2017
Start date
Sep 28, 2017
Primary completion
Apr 17, 2018
Completion
Apr 17, 2018
Results posted
Aug 6, 2019
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albuterol

Start the discussion